Ipilimumab (Yervoy ®) is a fully human anti human IgG1 monoclonal antibody and an immune-modulatory agent that has been developed for the treatment of melanoma, an aggressive form of skin cancer. Ipilimumab targets the protein CTLA-4. The monoclonal antibody influences the modulation of the immune response, weakens the inhibitory signal of CTLA-4 and therefore acts as an enhancer of T cell function.

The patent expired end of 2016, the extended patent protection last until 2022 and already several companies are developing biosimilar versions of Ipilimumab. PPS has generated considerable experience in the analysis of different originator batches as well as variants of biosimilars of Ipilimumab.

We have established an analytical program according to the ICH Q6B guidance, including the method setup, validation of customer specific methods and release testing.

This package includes different assays for protein quantification and characterizing the protein primary structure and secondary structure, as well as detailed analysis of N-glycosylation and protein modification.


Your contact for Ipilimumab at Protagen Protein Services GmbH

Martin-Blueggel 150x100px

Martin Blüggel

Chief Executive Officer (CEO)
Our business development team will be happy to assist you with your project.

Phone: +49 (0) 231 9742-6100
Email: salesproteinservices@ProtagenProteinServices.com